Table 1. Characteristics of Study Patients
DemographicsAllIschemicNonischemic
No. of patients2715 (55.6%)12 (44.4%)
Age, y (mean±SD)52.9±15.652.6±15.453.3±16.4
>65 years8 (29.6%)4 (26.7%)4 (33.3%)
Male25 (92.6%)13 (86.7%)12 (100%)
Risk factor
Hypertension11 (40.7%)10 (66.7%)1 (8.3%)
Hyperlipidemia12 (44.4%)11 (73.3%)1 (8.3%)
Diabetes mellitus5 (18.5%)5 (33.3%)0 (0.0%)
Oral medication4 (14.8%)4 (26.7%)0 (0.0%)
Insulin1 (3.7%)1 (6.7%)0 (0.0%)
Cardiac history
ICD implantation7 (25.9%)3 (20.0%)4 (33.3%)
CRT‐D implantation8 (29.6%)2 (13.3%)6 (50.0%)
Myocardial infarction15 (55.6%)15 (100%)0 (0.0%)
History of coronary revascularization
PCI10 (37.0%)10 (66.7%)0 (0.0%)
CABG6 (22.2%)6 (40.0%)0 (0.0%)
History of valve surgery
Mitral valve surgery10 (37.0%)2 (13.3%)8 (66.7%)
Aortic valve surgery1 (3.7%)1 (6.7%)0 (0.0%)
IABP0 (0.0%)0 (0.0%)0 (0.0%)
LVAD0 (0.0%)0 (0.0%)0 (0.0%)
Medication
ACE‐I18 (66.7%)10 (66.7%)8 (66.7%)
ARB9 (33.3%)7 (46.7%)2 (16.7%)
β‐blocker27 (100%)15 (100%)12 (100%)
Diuretics27 (100%)15 (100%)12 (100%)
Antiplatelet14 (51.9%)12 (80.0%)2 (16.7%)
Warfarin20 (74.1%)9 (60.0%)11 (91.7%)
Amiodarone9 (33.3%)2 (13.3%)7 (58.3%)
Statins13 (48.1%)12 (80.0%)1 (8.3%)
Continuous catecholamine infusion2 (7.4%)1 (6.7%)1 (8.3%)
  • ACE‐I indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CABG, coronary artery bypass grafting; CRT‐D, cardiac resynchronization‐defibrillator therapy; IABP, intra‐aortic balloon pump; ICD, implantable cardioverter defibrillator; LVAD, left ventricular assist device; PCI, percutaneous coronary intervention.